Salute e Benessere
Senior life science and medical specialists join SmartCella's Board of Directors
At the Annual General Meeting, (Professor of Surgery and Scientific Director Life Science at Karolinska Institutet ), (previously senior roles with Lonza, Thermo Fisher Scientific and Becton Dickinson and Company), and (PhD in Cardiovascular Physiology/Pharmacology and Senior Vice President and Global Head of Research and Early Development, Cardiovascular, Renal and Metabolic Diseases at AstraZeneca) were appointed new members of the SmartCella Board of Directors. , Partner and Global Head of Equity Capital Markets at private equity firm EQT, and founder and Chairperson, were re-elected. Thomas von Koch declined re-election.
Christian Kinch , Chairperson of SmartCella comments: "We founded SmartCella in 2014 and have since invested in science, clinical data, team development, and infrastructure. As we advance on our strategic journey, our new board members will bring immense value with their diverse backgrounds in academia, science, and the commercial aspects of global MedTech and life science companies. It is a testament to our strength that we can attract such high-caliber individuals to the Board, whose skills complement SmartCella's strong in-house team. I am excited and humbled by the potential of our collaboration and the impact SmartCella can have in addressing global health challenges, such as cardiovascular diseases and cancer. Our goal is to bring the magic behind medical science to transform lives, and I could not have a better Board of Directors to help achieve this vision." He continues: "I would like to extend my appreciation to Thomas von Koch for his dedication and support over the past ten years. His philosophy of future-proofing companies has significantly contributed to SmartCella's development. We look forward to continuing our collaboration with Thomas as an advisor and anchor investor."
Niklas Prager , CEO of SmartCella, says: "With a track record of exceeding our strategic commitments, I am delighted to continue developing SmartCella and collaborating closely with all the Board members. The SmartCella Board now encompasses comprehensive expertise across all relevant domains, including equity capital markets, biotechnology, life sciences, MedTech, as well as medical, clinical, and research. I believe this breadth of knowledge is truly unique and essential to SmartCella. For us, a solid scientific foundation is crucial, and we rely on evidence-based science rather than speculative scenarios with limited substance. We are well-positioned to significantly disrupt disease treatment and make cutting-edge therapies safely accessible to a wide range of patients in a not too distant future."
Nina Nornholm , Head of Corporate Communication +46 708 550 356 nina.nornholm@smartcella.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/smartcella-holding-ab/r/senior-life-science-and-medical-specialists-join-smartcella-s-board-of-directors,c3999505
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/senior-life-science-and-medical-specialists-join-smartcellas-board-of-directors-302170525.html